Crimean-Congo Hemorrhagic Fever Survivors Elicit Protective Non-Neutralizing Antibodies that Target 11 Overlapping Regions on Viral Glycoprotein GP38
Olivia S. Shin, Stephanie R. MonticelliiD, Christy K. HjorthiD, Vladlena HornetiD, Michael Doyle, Dafna M. AbelsoniD, Ana I. Kuehne, Albert WangiD, Russell R. BakkeniD, Akaash Kumar MishraiD, Marissa MiddlecampiD, Elizabeth R. ChampneyiD, Lauran Stuart, Daniel P. MaureriD, Jiannan LiiD, Jacob L. BerriganiD, Jennifer Barajas, Stephen Karabyo BalinandiiD, Julius Julian LutwamaiD, Leslie I. Lobel, Larry ZeitliniD, Laura M. WalkeriD, John M. DyeiD, Kartik ChandraniD, Andrew S. HerbertiD, , Jason S. McLellaniD
Abstract
Crimean-Congo hemorrhagic fever virus can cause lethal disease in humans yet there are no approved medical countermeasures. Viral glycoprotein GP38, unique to Nairoviridae, is a target of protective antibodies, but extensive mapping of the human antibody response to GP38 has not been previously performed. Here, we isolated 188 GP38-specific antibodies from human survivors of infection. Competition experiments showed that these antibodies bind across five distinct antigenic sites, encompassing eleven overlapping regions. Additionally, we reveal structures of GP38 bound with nine of these antibodies targeting different antigenic sites. Although GP38-specific antibodies were non-neutralizing, several antibodies were found to have protection equal to or better than murine antibody 13G8 in two highly stringent rodent models of infection. Together, these data expand our understanding regarding this important viral protein and inform the development of broadly effective CCHFV antibody therapeutics.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 21
- FWCI
- 6.31
- Field percentile
- top 2%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antibodies targeting Crimean-Congo hemorrhagic fever virus GP38 limit vascular leak and viral spread
Felix Pahmeier, Stephanie R. Monticelli, … Eva Harris·Science Translational MedicinePeer-reviewed·Feb 19, 2025
- Engineering, structure, and immunogenicity of a Crimean-Congo hemorrhagic fever virus pre-fusion heterotrimeric glycoprotein complex
Elizabeth McFadden, Stephanie R. Monticelli, … Jason S. McLellan·CellPeer-reviewed·Dec 18, 2024
- Dual-Antigen CCHFV Vaccine Induces Neutralizing Immunity and Protection Against Lethal Challenge
Jingyi Yan, Lara Sweetapple, … Gustaf Ahlén·bioRxiv·Oct 13, 2026
- A single-dose recombinant rVSVΔG-CCHFV-GPC vaccine protects nonhuman primates against heterologous Crimean-Congo hemorrhagic fever virus challenge
Robert W. Cross, Kevin Melody, … Thomas W. Geisbert·bioRxiv·Oct 22, 2026
- Human Cytomegalovirus antagonizes activation of Fcγ receptors II and III by distinct and synergizing modes of IgG manipulation
P. Kolb, K. Hoffmann, … H. Hengel·bioRxiv·Oct 12, 2020
- Improving antibody-mediated protection against HSV infection by eliminating interactions with the viral Fc receptor gE/gI
Matthew D. Slein, Iara M. Backes, … Margaret E. Ackerman·Science Translational MedicinePeer-reviewed·Nov 19, 2025